Search - tctmd.com

Displaying 1 - 20 of 67

Sort: Relevancy | Date

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

March 12, 2025

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

November 16, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

News Conference News ESC 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

August 31, 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

February 15, 2024

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

August 30, 2023

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

News Conference News ESOC 2023

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

May 25, 2023

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

November 11, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

News Conference News HRS 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

April 29, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.